Clinical trials: Autoimmunity
Neurological Autoimmune Diseases
A Study of HY001N in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases
This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory…
- Trial name
- NCT07265206
- Testing
- HY001N cell injection
- Volunteers
- 15 people
- Sponsor
- Juventas Cell Therapy Ltd.
Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the safety and tolerability of TAK-079 in comparison with matching placebo, administered once every 3 weeks over a 12-week dosing period in participants with active SLE who are receiving…
- Trial name
- NCT03724916
- Testing
- TAK-079
- Where
- 19 sites in United States
- Volunteers
- 23 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Spasticity, Multiple Sclerosis
Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis.
- Trial name
- NCT01868048
- Testing
- Sativex
- Sponsor
- GW Research Ltd
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic
A Non-drug Study Profiling Cutaneous Lupus
The purpose of this study is to characterize the clinical and molecular profiles of patients with cutaneous lupus.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
- Trial name
- NCT01923415
- Testing
- No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
- Where
- 3 sites in United States, Poland
- Volunteers
- 29 people
- Sponsor
- Janssen Research & Development, LLC
Lupus Nephritis, Systemic Lupus Erythematosus
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and preliminary efficacy of ATA3219 for treatment of participants with lupus nephritis (LN) following lymphodepletion (LD) and in participants with extrarenal systemic lupus…
- Trial name
- NCT06429800
- Testing
- ATA3219
- Where
- United States
- Sponsor
- Atara Biotherapeutics
Systemic Lupus Erythematosus (SLE)
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus
This study is a single-arm, open-label clinical study designed to evaluate the safety and tolerability of QT-019B in subjects with refractory SLE and to determine the RD.
- Trial name
- NCT07444307
- Testing
- QT-019B Cell Injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Hangzhou Qihan Biotech Co., Ltd.
Polyneuropathy, Inflammatory Demyelinating, Chronic
Real-world Study of Treatment Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy/Polyradiculoneuropathy (CIDP)
This study is an observational, ambispective, descriptive, non-interventional study of people with a chronic inflammatory demyelinating polyneuropathy/polyradiculoneuropathy (CIDP) diagnosis in the United States with residual…
- Trial name
- ORBIT-CIDP (NCT06968975)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Sanofi
Diabetes Mellitus, Diabetes Mellitus, Type 1
An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D
This is an open-label, multicenter, Phase 1 study evaluating the safety and tolerability of VCTX210A combination product in patients with T1D
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- NCT05210530
- Testing
- VCTX210A unit
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- CRISPR Therapeutics AG
Multiple Sclerosis
Therapy Optimization in Multiple Sclerosis (MS)
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
- Trial name
- TOP MS (NCT00819000)
- Testing
- Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
- Where
- 3 sites in United States
- Volunteers
- 2,878 people
- Sponsor
- Teva Neuroscience, Inc.
SLE - Systemic Lupus Erythematosus
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
This study is a randomized, double-blind, placebo-controlled Phase I clinical trial featuring single and multiple ascending doses.
- Trial name
- NCT07177911
- Testing
- CC312
- Where
- China
- Volunteers
- 32 people
- Sponsor
- CytoCares Inc
Chronic Inflammatory Disorder, Arthritis, Rheumatoid
A Relative Bioavailability and Food Effect Study of New Formulations
The purpose of this trial is to assess the effect of 3 formulations on the relative bioavailability of LY3009104. Participants will receive single dose of LY3009104 on 4 separate occasions with and without food.
- Trial name
- NCT01398475
- Testing
- LY3009104
- Where
- Singapore
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis, Osteoarthritis
Cementless Alumina-Alumina Total Hip and Hybrid
Evaluate the safety and efficacy of the CeramTec Acetabular Alumina Insert and CeramTec Alumina head when used with the Foundation Porous Coated Acetabular Shell and an Encore hip stem.
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis
- Trial name
- NCT00764530
- Testing
- Alumina/Alumina, Standard
- Where
- 3 sites in United States
- Volunteers
- 342 people
- Sponsor
- Encore Medical, L.P.
Rheumatoid Arthritis
Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis
This Phase IV post-marketing, non-interventional, open label, non-comparative and prospective study will examine the efficacy and safety of rituximab in participants who had previously received rituximab in terms of everyday…
- Trial name
- RITAM (NCT02699892)
- Testing
- Rituximab
- Where
- 4 sites in Serbia
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)
The purpose of this study is to evaluate the proportion of Rheumatoid Arthritis (RA) subjects achieving a "good" or "moderate" DAS28 response (EULAR28 criteria) at Week 16 with etanercept 50 mg subcutaneously (SC) once weekly in…
- Trial name
- NCT00099554
- Testing
- Etanercept
- Volunteers
- 200 people
- Sponsor
- Amgen
Pemphigus
A Clinical Study of B007 in the Treatment of Pemphigus.
The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with pemphigus.
- Trial name
- NCT06454357
- Testing
- B007
- Where
- 12 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Rheumatoid Arthritis
Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)
To evaluate the efficacy of Diacerein 100 mg daily versus placebo in reducing rheumatoid arthritis symptoms, when added to stable oral MTX therapy in patients with active early RA.
- Trial name
- NCT01264211
- Testing
- Diacerein
- Where
- 2 sites in Thailand
- Volunteers
- 40 people
- Sponsor
- TRB Chemedica
Arthritis, Rheumatoid, Spondyloarthritis, Axial
Biologic Treatment Registry Across Canada
This registry is a multi-center, prospective, longitudinal, observational program that will gather and analyse data on participants treated with infliximab, golimumab, golimumab Intravenous (I.V) or ustekinumab.
- Conditions
- Arthritis, Rheumatoid, Spondyloarthritis, Axial, Arthritis, Psoriatic
- Trial name
- BioTRAC (NCT00741793)
- Where
- Canada
- Volunteers
- 2,821 people
- Sponsor
- Janssen Inc.
Systemic Lupus Erythematosus
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KP104 in participants with systemic lupus erythematosus (SLE)-Thrombotic microangiopathy (TMA).
- Trial name
- NCT05504187
- Testing
- KP104
- Volunteers
- 24 people
- Sponsor
- Kira Pharmacenticals (US), LLC.
Arthritis, Rheumatoid
A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the efficacy and safety of nipocalimab versus placebo in participants with moderate to severe active rheumatoid arthritis (RA).
- Trial name
- NCT04991753
- Testing
- Nipocalimab
- Where
- 28 sites in United States, Germany and 3 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®
This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin…
- Trial name
- NCT01984372
- Testing
- insulin degludec
- Where
- Japan
- Volunteers
- 6,163 people
- Sponsor
- Novo Nordisk A/S